1. Generics Bulletin
  2. >>Market Intelligence
  3. >>Pricewatch UK

UK Gabapentin Prices Shoot Up In December

Pricewatch UK – December 2024

 
• By Dave Wallace

UK prices for gabapentin almost trebled in December, according to the latest figures from WaveData.

Price Watch UK
• Source: Alamy

Average UK trade prices for the 600mg tablet presentation of gabapentin shot up in December, rising by almost three times on average, according to the latest figures from market researcher WaveData.

Based on trade prices to UK independent pharmacists, WaveData found that gabapentin 600mg tablets had risen by 195% on average...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricewatch UK

UK Pioglitazone Prices Go Through The Roof Among A Raft Of May Rises

 
• By Dave Wallace

As multiple molecules experienced triple-digit percentage price rises in May, pioglitazone once again led the way after already topping our table of price increases in April.

Pioglitazone Prices Peak In April As Multiple UK Molecules Double In Price

 
• By Dave Wallace

Diabetes medication pioglitazone topped the list of the fastest-rising UK generics prices in April, according to market researcher WaveData.

Trihexyphenidyl Tablets Treble In A Busy March For UK Price Rises

 
• By Dave Wallace

Trihexyphenidyl tablets in two different strengths led a raft of UK generic price rises in March, according to the latest figures from WaveData.

Trimethoprim Trebles As Last Month’s UK Fallers Bounce Back

 
• By Dave Wallace

In a month that saw the average prices of five generic presentations more than double in the UK, WaveData’s figures showed trimethoprim leading the rises with an enormous price increase in February, as several products bounced back from declines in the previous month.

More from Generics Bulletin

‘Disappointed’ Lipella Seeks Alternatives Following Nasdaq Delisting

 
• By Dean Rudge

Clinical-stage reformulation specialist Lipella Pharmaceuticals has insisted that “our commitment to our shareholders, our mission, and our clinical goals has not changed” after its common stock was delisted from the Nasdaq Capital Market.

Viatris Targets Gilead’s Odefsey HIV Blockbuster In Europe With CHMP Recommendation

 
• By Dean Rudge

Viatris has secured two positive opinions from the European Medicines Agency’s Committee for Medicinal Products for Human Use for generics to two blockbusters: Gilead’s HIV drug Odefsey and Boehringer’s IPF treatment Ofev, with a path to approvals possible in 67 days.

AAM Celebrates Court Backing Over Minnesota Pricing Law

 
• By Dave Wallace

The AAM has welcomed a US appeals court decision backing an injunction against a Minnesota state law on drug pricing, following an earlier favorable district court ruling.